Cynthia L Clark

Address:

11311 Sir Winston St APT 101, San Antonio, TX 78216

VIN:

JTDKB20U777631234

Make:

TOYOTA

Model:

PRIUS

Year:

2007

US Patent:

7589212, Sep 15, 2009

Filed:

Jun 26, 2007

Appl. No.:

11/821868

Inventors:

Jeffrey Lyle Gray - Loveland OH, US
Kande K. D. Amarasinghe - Latham NY, US
Cynthia Monesa Clark - Concord MA, US
Ryan Matthew Nichols - Cincinnati OH, US
Matthew B. Maier - Springboro OH, US

Assignee:

Procter & Gamble Company - Cincinnati OH

International Classification:

A61K 31/433
C07D 417/12

US Classification:

548138, 514363

Abstract:

The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising one or more human protein tyrosine phosphatase beta (HPTP-β) inhibitors, and to methods for regulating angiogenesis.

US Patent:

7622593, Nov 24, 2009

Filed:

Jun 26, 2007

Appl. No.:

11/823086

Inventors:

Jeffrey Lyle Gray - Loveland OH, US
Kande K. D. Amarasinghe - Latham NY, US
Cynthia Monesa Clark - Concord MA, US
Ryan Matthew Nichols - Cincinnati OH, US
Matthew B. Maier - Springboro OH, US

Assignee:

The Procter & Gamble Company - Cincinnati OH

International Classification:

A61K 31/426
C07D 277/30

US Classification:

548204, 514365

Abstract:

The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising said human protein tyrosine phosphatase beta (HPTP-β) inhibitors, and to methods for regulating angiogenesis.

US Patent:

7795444, Sep 14, 2010

Filed:

Jun 26, 2007

Appl. No.:

11/821846

Inventors:

Jeffrey Lyle Gray - Loveland OH, US
Kande K. D. Amarasinghe - Latham NY, US
Cynthia Monesa Clark - Concord MA, US
Ryan Matthew Nichols - Cincinnati OH, US
Matthew B. Maier - Springboro OH, US

Assignee:

Warner Chilcott Company - Fajardo PR

International Classification:

C07D 277/30
A61K 31/426

US Classification:

548204, 514365

Abstract:

The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising said human protein tyrosine phosphatase beta (HPTP-β) inhibitors, and to methods for regulating angiogenesis.

US Patent:

8106078, Jan 31, 2012

Filed:

Aug 4, 2010

Appl. No.:

12/850026

Inventors:

Jeffrey Lyle Gray - Loveland OH, US
Kande K. D. Amarasinghe - Latham NY, US
Cynthia Monesa Clark - Concord MA, US
Ryan Matthew Nichols - Cincinnati OH, US
Matthew B. Maier - Springboro OH, US

Assignee:

Warner Chilcott Company, LLC - Rajardo PR

International Classification:

A61K 31/426
C07D 277/30

US Classification:

514365, 548204

Abstract:

The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising said human protein tyrosine phosphatase beta (HPTP-β) inhibitors, and to methods for regulating angiogenesis.

US Patent:

8188125, May 29, 2012

Filed:

May 18, 2009

Appl. No.:

12/467430

Inventors:

Jeffrey Lyle Gray - Loveland OH, US
Kande K. D. Amarasinghe - Latham NY, US
Cynthia Monesa Clark - Concord MA, US
Ryan Matthew Nichols - Cincinnati OH, US
Matthew B. Maier - Springboro OH, US

Assignee:

Aerpio Therapeutics Inc. - Cincinnati OH

International Classification:

A61K 31/433

US Classification:

514363

Abstract:

The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising one or more human protein tyrosine phosphatase beta (HPTP-β) inhibitors, and to methods for regulating angiogenesis.

US Patent:

8258311, Sep 4, 2012

Filed:

Nov 23, 2009

Appl. No.:

12/624072

Inventors:

Jeffrey Lyle Gray - Loveland OH, US
Kande K. D. Amarasinghe - Latham NY, US
Cynthia Monesa Clark - Concord MA, US
Ryan Matthew Nichols - Cincinnati OH, US
Matthew B. Maier - Springboro OH, US

Assignee:

Aerpio Therapeutics Inc. - Cincinnati OH

International Classification:

A61K 31/426
A61K 31/427
C07D 277/30
C07D 417/04

US Classification:

548204, 514365

Abstract:

The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising said human protein tyrosine phosphatase beta (HPTP-β) inhibitors, and to methods for regulating angiogenesis.

US Patent:

8338615, Dec 25, 2012

Filed:

Dec 1, 2011

Appl. No.:

13/309452

Inventors:

Jeffrey Lyle Gray - Loveland OH, US
Kande K. D. Amarasinghe - Latham NY, US
Cynthia Monesa Clark - Concord MA, US
Ryan Matthew Nichols - Cincinnati OH, US
Matthew B. Maier - Springboro OH, US

Assignee:

Aerpio Therapeutics Inc. - Cincinnati OH

International Classification:

A61K 31/433
C07D 417/12

US Classification:

548138, 514363

Abstract:

The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising one or more human protein tyrosine phosphatase beta (HPTP-β) inhibitors, and to methods for regulating angiogenesis.

US Patent:

20030225082, Dec 4, 2003

Filed:

Mar 5, 2003

Appl. No.:

10/382060

Inventors:

Matthew Laufersweiler - Morrow OH, US
Cynthia Crago Clark - Loveland OH, US
Michael Clark - Loveland OH, US
Jane Djung - Mason OH, US
Biswanath De - Cincinnati OH, US
Michael Natchus - Alpharetta GA, US

International Classification:

A61K031/5377
A61K031/506
C07D413/14
C 07D 4 3/02

US Classification:

514/235800, 514/275000, 544/122000, 544/324000

Abstract:

The present invention relates to compounds which are capable of preventing the extracellular release of inflammatory cytokines, said compounds, or enantiomeric and diasteriomeric forms or pharmaceutically acceptable salts thereof, have the formula: wherein R is an ether or amino unit, Ris substituted phenyl, each Rand Runit is independently selected from the group consisting of: a) hydrogen; and b) substituted or unsubstituted C-Chydrocarbyl selected from the group consisting of: i) C-Clinear, branched or cyclic alkyl; ii) C-Caryl; iii) C-Cheterocyclic; iv) C-Cheteroaryl.